Pricing Log in Create free account

Freenome, Inc (FRNM) vs NeoGenomics, Inc. (NEO)

Freenome, Inc and NeoGenomics, Inc. are both Diagnostics & Research companies. NeoGenomics, Inc. is the larger, with a market value of $2.1B against $1.1B — 1.9× the size. Freenome, Inc has the higher net margin (0.00% vs −4.10%) and the higher return on invested capital (0.00% vs −2.97%). Across the 12 metrics below, Freenome, Inc leads on 7 and NeoGenomics, Inc. on 5.

Valuation

Metric FRNM NEO Diagnostics & Research median
P/E n/m n/m 34.52
P/S n/m 2.70 4.24
P/B n/m 2.66 3.42
Price to free cash flow n/m n/m 33.51
EV/EBITDA n/m 146.75 23.44
EV/Sales n/m 3.26 5.18
Earnings yield (2.98%) (1.50%) (1.50%)
Free cash flow yield (3.55%) (1.25%) 0.00%

Profitability

Metric FRNM NEO Diagnostics & Research median
Gross margin — 44.77% 48.32%
Operating margin 0.00% (6.27%) (5.68%)
Net margin 0.00% (4.10%) (4.10%)
Free cash flow margin 0.00% (3.37%) 0.00%
Return on equity 17.81% (3.94%) 0.00%
Return on assets (0.86%) (2.35%) (6.05%)
Return on invested capital 0.00% (2.97%) 0.00%

Growth

Metric FRNM NEO Diagnostics & Research median
Revenue growth (TTM) — 11.08% 8.99%
EPS growth (last fiscal year) (58.34%) (35.48%) 20.36%
Revenue growth, 5-year CAGR — 10.35% 7.30%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric FRNM NEO Diagnostics & Research median
Debt to equity 0.00 0.47 0.01
Current ratio 0.20 3.53 2.27
Net debt to EBITDA 0.29 (3.96) 0.68

Dividend

Metric FRNM NEO Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric FRNM NEO Diagnostics & Research median
Market cap 1.12b 2.13b 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack